Tandem Diabetes Care (TNDM) Net Cash Flow (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Net Cash Flow for 14 consecutive years, with -$119.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 1443.03% year-over-year to -$119.8 million; the trailing twelve-month figure through Jun 2026 stood at -$5.4 million (down 134.75% YoY), and the FY2025 full-year result was $19.8 million, up 117.21% from the prior year.
• Net Cash Flow retreated to -$119.8 million in Q2 2026 per TNDM's latest filing, from $89.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $89.8 million in Q1 2026 and bottomed at -$119.8 million in Q2 2026.
• Historically, Net Cash Flow has averaged -$781944.4 across 5 years, with a median of $2.8 million in 2023.
• The widest YoY moves for Net Cash Flow: up 1051.86% in 2025, down 2680.52% in 2025.
• Over 5 years, Net Cash Flow stood at $47.7 million in 2022, then plunged by 144.41% to -$21.2 million in 2023, then surged by 185.11% to $18.0 million in 2024, then slumped by 114.33% to -$2.6 million in 2025, then slumped by 4538.48% to -$119.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$119.8 million, $89.8 million, and -$2.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.